Goldman Sachs Small Cap Eq Insghts Fd earns an Above Average Process Pillar rating. The largest contributor to the rating is the fund's impressive long-term risk-adjusted performance. This can be ...

Blueprint Medicines (BPMC) sees strong AYVAKIT growth, 2025 revenue guidance at $680M-$710M. Discover insights on their market expansion & $2B 2030 vision.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Blueprint Medicines Corp (NASDAQ:BPMC) reported a challenging fourth quarter for 2024, missing analyst expectations for both earnings per share (EPS) and revenue. The company posted an EPS of -0.79, ...

Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of -$1.44 compared to the forecast of -$1.68. The company also ...

Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...

These companies have stood the test of time and are respected by their ... Berkshire Hathaway, Goldman Sachs Group, Home Depot, Intel, JPMorgan Chase, Kenvue, Mastercard, Merck, Microsoft, Nike ...